Exjade (Deferasirox (Dispersible)) 125mg

Exjade (deferasirox 125mg dispersible tablets) is an oral iron chelator used to reduce chronic iron overload in patients receiving frequent blood transfusions. This medication helps manage iron levels in the body to prevent complications from excess iron buildup.

Strength

125mg

Pack Size

28s

Storage

Ambient

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Exjade is primarily used to treat chronic iron overload caused by frequent blood transfusions in conditions like thalassemia, sickle cell disease, or other anemias. It works by binding to excess iron in the bloodstream and helping the body remove it through urine and stool. Patients often ask, 'what is Exjade used for' when managing iron overload from transfusions.

Side Effects

Exjade helps lower iron levels in the body over time, reducing the risk of iron-related complications such as organ damage. Some users may notice changes in urine color or mild gastrointestinal effects like nausea or stomach upset as the body adjusts to the medication.

Precautions & Warnings

Exjade should be taken once daily on an empty stomach, at least 30 minutes before food, with a glass of water. It is important to stay well-hydrated while taking this medication to support kidney function. Regular monitoring of blood iron levels and kidney function is recommended during treatment.

Avoid Interactions

Exjade may interact with other medications that affect liver enzymes, such as certain antibiotics or antifungals, potentially altering its effectiveness. Combining it with alcohol or other substances that stress the liver should be avoided. Always inform your healthcare provider about all medications and supplements you are taking.

References

Frequently Asked Questions

Exjade is used to reduce chronic iron overload in patients who receive frequent blood transfusions, such as those with thalassemia or sickle cell disease.

Exjade should be taken once daily on an empty stomach, at least 30 minutes before food, with a full glass of water.

Common side effects may include nausea, stomach upset, or changes in urine color. Kidney function should be monitored regularly.

No, Exjade should be taken on an empty stomach to ensure proper absorption and effectiveness.

Patients with severe kidney disease or certain liver conditions should use Exjade with caution and under medical supervision.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.